Constitutive Nuclear Localization of an Alternatively Spliced Sirtuin-2 Isoform
Overview
Molecular Biology
Affiliations
Sirtuin-2 (SIRT2), the cytoplasmic member of the sirtuin family, has been implicated in the deacetylation of nuclear proteins. Although the enzyme has been reported to be located to the nucleus during G2/M phase, its spectrum of targets suggests functions in the nucleus throughout the cell cycle. While a nucleocytoplasmic shuttling mechanism has been proposed for SIRT2, recent studies have indicated the presence of a constitutively nuclear isoform. Here we report the identification of a novel splice variant (isoform 5) of SIRT2 that lacks a nuclear export signal and encodes a predominantly nuclear isoform. This novel isoform 5 fails to show deacetylase activity using several assays, both in vitro and in vivo, and we are led to conclude that this isoform is catalytically inactive. Nevertheless, it retains the ability to interact with p300, a known interaction partner. Moreover, changes in intrinsic tryptophan fluorescence upon denaturation indicate that the protein is properly folded. These data, together with computational analyses, confirm the structural integrity of the catalytic domain. Our results suggest an activity-independent nuclear function of the novel isoform.
Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity.
Shenk T, Kulp Iii J, Chiang L Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458938 PMC: 11510315. DOI: 10.3390/ph17101298.
Biophysical insights into the dimer formation of human Sirtuin 2.
Suzuki N, Konuma T, Ikegami T, Akashi S Protein Sci. 2024; 33(5):e4994.
PMID: 38647411 PMC: 11034489. DOI: 10.1002/pro.4994.
Piracha Z, Saeed U, Piracha I, Noor S, Noor E Front Cell Infect Microbiol. 2024; 13:1234903.
PMID: 38239506 PMC: 10794644. DOI: 10.3389/fcimb.2023.1234903.
Sola-Sevilla N, Mesa-Lombardo A, Aleixo M, Exposito S, Diaz-Perdigon T, Azqueta A J Neuroimmune Pharmacol. 2023; 18(3):529-550.
PMID: 37698780 PMC: 10577113. DOI: 10.1007/s11481-023-10084-9.
Roche K, Remiszewski S, Todd M, Kulp 3rd J, Tang L, Welsh A J Clin Invest. 2023; 133(12).
PMID: 37317966 PMC: 10266789. DOI: 10.1172/JCI158978.